Global Peri implantitis Market
Global Peri implantitis Market

Peri implantitis Comprehensive Study by Type (Non-surgical treatment, Surgical treatment), Therapy Class (Class-1, Classs-2, Class-3, Class-4), Severity (Early(PD>=4mm), Moderate(PD>=6mm), Advanced(PD>=8mm)), End User (Hospitals, Clinics) Players and Region - Global Market Outlook to 2026

Peri implantitis Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 234 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Peri implantitis Market Scope?
Peri-implantitis is an infectious disease that causes gum and bone structure inflammation around a dental implant. Chronic inflammation causes bone loss, which can result in a loose implant that may fall out eventually. Because implant attachments are more fragile than natural teeth, the risk of inflammation and peri-implantitis is much higher with implants. If the gums around the implants are loose, harmful bacteria can grow beneath the gums, causing bone loss.

The Peri implantitis market study is being classified by Type (Non-surgical treatment and Surgical treatment) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Peri implantitis market throughout the predicted period.

Geistlich Pharma Inc. (Switzerland), Aetna Inc. (United States), Dawood & Tanner (United Kingdom), Neoss (United Kingdom), Pfizer Inc. (United States), Cadila Pharmaceuticals (India), R.N. Laboratories Pvt. Ltd. (United States), Basic Pharma Life Science Pvt. Ltd. (India), Prachi Pharmaceuticals Private Limited. (India) and Geistlich Pharma Inc. (Switzerland) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Peri implantitis market by Type, Application and Region.

On the basis of geography, the market of Peri implantitis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • The surge in the incidence of peri-implantitis
  • Rise In Behavioral Risk Factors Like Smoking And Diabetes

Market Drivers
  • Increase in the number of dental procedures
  • Growing concern towards oral hygien
  • Advent Of Technological Advancements Pertaining To Dental Procedure

Opportunities
  • The growing number of the oral diseases

Restraints
  • High cost of dental procedures

Challenges
  • Lack of awareness and shortage of skilled people


Key Target Audience
New Entrants/Investors, Analysts and Strategic Planners, Peri implantitis Providers, Government Regulatory and Research Organizations and End User

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Peri implantitis market expands?
The Global Peri implantitis market is expected to see a growth of % during projected year 2020 to 2026.

2. Who are the prominent players of the Global Peri implantitis market?
The prominent players of Global Peri implantitis market are Geistlich Pharma Inc. (Switzerland), Aetna Inc. (United States), Dawood & Tanner (United Kingdom), Neoss (United Kingdom), Pfizer Inc. (United States), Cadila Pharmaceuticals (India), R.N. Laboratories Pvt. Ltd. (United States), Basic Pharma Life Science Pvt. Ltd. (India), Prachi Pharmaceuticals Private Limited. (India) and Geistlich Pharma Inc. (Switzerland), to name a few.

3. What are the top priorities to focus for Peri implantitis marketís growth?
In this highly competitive & fast evolving Peri implantitis industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Type
  • Non-surgical treatment
  • Surgical treatment
By Therapy Class
  • Class-1
  • Classs-2
  • Class-3
  • Class-4

By Severity
  • Early(PD>=4mm)
  • Moderate(PD>=6mm)
  • Advanced(PD>=8mm)

By End User
  • Hospitals
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the number of dental procedures
      • 3.2.2. Growing concern towards oral hygien
      • 3.2.3. Advent Of Technological Advancements Pertaining To Dental Procedure
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness and shortage of skilled people
    • 3.4. Market Trends
      • 3.4.1. The surge in the incidence of peri-implantitis
      • 3.4.2. Rise In Behavioral Risk Factors Like Smoking And Diabetes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Peri implantitis, by Type, Therapy Class, Severity, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Peri implantitis (Value)
      • 5.2.1. Global Peri implantitis by: Type (Value)
        • 5.2.1.1. Non-surgical treatment
        • 5.2.1.2. Surgical treatment
      • 5.2.2. Global Peri implantitis by: Therapy Class (Value)
        • 5.2.2.1. Class-1
        • 5.2.2.2. Classs-2
        • 5.2.2.3. Class-3
        • 5.2.2.4. Class-4
      • 5.2.3. Global Peri implantitis by: Severity (Value)
        • 5.2.3.1. Early(PD>=4mm)
        • 5.2.3.2. Moderate(PD>=6mm)
        • 5.2.3.3. Advanced(PD>=8mm)
      • 5.2.4. Global Peri implantitis by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
      • 5.2.5. Global Peri implantitis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Peri implantitis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Geistlich Pharma Inc. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Aetna Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dawood & Tanner (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Neoss (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cadila Pharmaceuticals (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. R.N. Laboratories Pvt. Ltd. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Basic Pharma Life Science Pvt. Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Prachi Pharmaceuticals Private Limited. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Geistlich Pharma Inc. (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Peri implantitis Sale, by Type, Therapy Class, Severity, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Peri implantitis (Value)
      • 7.2.1. Global Peri implantitis by: Type (Value)
        • 7.2.1.1. Non-surgical treatment
        • 7.2.1.2. Surgical treatment
      • 7.2.2. Global Peri implantitis by: Therapy Class (Value)
        • 7.2.2.1. Class-1
        • 7.2.2.2. Classs-2
        • 7.2.2.3. Class-3
        • 7.2.2.4. Class-4
      • 7.2.3. Global Peri implantitis by: Severity (Value)
        • 7.2.3.1. Early(PD>=4mm)
        • 7.2.3.2. Moderate(PD>=6mm)
        • 7.2.3.3. Advanced(PD>=8mm)
      • 7.2.4. Global Peri implantitis by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
      • 7.2.5. Global Peri implantitis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Peri implantitis: by Type(USD Million)
  • Table 2. Peri implantitis Non-surgical treatment , by Region USD Million (2015-2020)
  • Table 3. Peri implantitis Surgical treatment , by Region USD Million (2015-2020)
  • Table 4. Peri implantitis: by Therapy Class(USD Million)
  • Table 5. Peri implantitis Class-1 , by Region USD Million (2015-2020)
  • Table 6. Peri implantitis Classs-2 , by Region USD Million (2015-2020)
  • Table 7. Peri implantitis Class-3 , by Region USD Million (2015-2020)
  • Table 8. Peri implantitis Class-4 , by Region USD Million (2015-2020)
  • Table 9. Peri implantitis: by Severity(USD Million)
  • Table 10. Peri implantitis Early(PD>=4mm) , by Region USD Million (2015-2020)
  • Table 11. Peri implantitis Moderate(PD>=6mm) , by Region USD Million (2015-2020)
  • Table 12. Peri implantitis Advanced(PD>=8mm) , by Region USD Million (2015-2020)
  • Table 13. Peri implantitis: by End User(USD Million)
  • Table 14. Peri implantitis Hospitals , by Region USD Million (2015-2020)
  • Table 15. Peri implantitis Clinics , by Region USD Million (2015-2020)
  • Table 16. South America Peri implantitis, by Country USD Million (2015-2020)
  • Table 17. South America Peri implantitis, by Type USD Million (2015-2020)
  • Table 18. South America Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 19. South America Peri implantitis, by Severity USD Million (2015-2020)
  • Table 20. South America Peri implantitis, by End User USD Million (2015-2020)
  • Table 21. Brazil Peri implantitis, by Type USD Million (2015-2020)
  • Table 22. Brazil Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 23. Brazil Peri implantitis, by Severity USD Million (2015-2020)
  • Table 24. Brazil Peri implantitis, by End User USD Million (2015-2020)
  • Table 25. Argentina Peri implantitis, by Type USD Million (2015-2020)
  • Table 26. Argentina Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 27. Argentina Peri implantitis, by Severity USD Million (2015-2020)
  • Table 28. Argentina Peri implantitis, by End User USD Million (2015-2020)
  • Table 29. Rest of South America Peri implantitis, by Type USD Million (2015-2020)
  • Table 30. Rest of South America Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 31. Rest of South America Peri implantitis, by Severity USD Million (2015-2020)
  • Table 32. Rest of South America Peri implantitis, by End User USD Million (2015-2020)
  • Table 33. Asia Pacific Peri implantitis, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Peri implantitis, by Type USD Million (2015-2020)
  • Table 35. Asia Pacific Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 36. Asia Pacific Peri implantitis, by Severity USD Million (2015-2020)
  • Table 37. Asia Pacific Peri implantitis, by End User USD Million (2015-2020)
  • Table 38. China Peri implantitis, by Type USD Million (2015-2020)
  • Table 39. China Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 40. China Peri implantitis, by Severity USD Million (2015-2020)
  • Table 41. China Peri implantitis, by End User USD Million (2015-2020)
  • Table 42. Japan Peri implantitis, by Type USD Million (2015-2020)
  • Table 43. Japan Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 44. Japan Peri implantitis, by Severity USD Million (2015-2020)
  • Table 45. Japan Peri implantitis, by End User USD Million (2015-2020)
  • Table 46. India Peri implantitis, by Type USD Million (2015-2020)
  • Table 47. India Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 48. India Peri implantitis, by Severity USD Million (2015-2020)
  • Table 49. India Peri implantitis, by End User USD Million (2015-2020)
  • Table 50. South Korea Peri implantitis, by Type USD Million (2015-2020)
  • Table 51. South Korea Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 52. South Korea Peri implantitis, by Severity USD Million (2015-2020)
  • Table 53. South Korea Peri implantitis, by End User USD Million (2015-2020)
  • Table 54. Taiwan Peri implantitis, by Type USD Million (2015-2020)
  • Table 55. Taiwan Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 56. Taiwan Peri implantitis, by Severity USD Million (2015-2020)
  • Table 57. Taiwan Peri implantitis, by End User USD Million (2015-2020)
  • Table 58. Australia Peri implantitis, by Type USD Million (2015-2020)
  • Table 59. Australia Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 60. Australia Peri implantitis, by Severity USD Million (2015-2020)
  • Table 61. Australia Peri implantitis, by End User USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Peri implantitis, by Type USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Peri implantitis, by Severity USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Peri implantitis, by End User USD Million (2015-2020)
  • Table 66. Europe Peri implantitis, by Country USD Million (2015-2020)
  • Table 67. Europe Peri implantitis, by Type USD Million (2015-2020)
  • Table 68. Europe Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 69. Europe Peri implantitis, by Severity USD Million (2015-2020)
  • Table 70. Europe Peri implantitis, by End User USD Million (2015-2020)
  • Table 71. Germany Peri implantitis, by Type USD Million (2015-2020)
  • Table 72. Germany Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 73. Germany Peri implantitis, by Severity USD Million (2015-2020)
  • Table 74. Germany Peri implantitis, by End User USD Million (2015-2020)
  • Table 75. France Peri implantitis, by Type USD Million (2015-2020)
  • Table 76. France Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 77. France Peri implantitis, by Severity USD Million (2015-2020)
  • Table 78. France Peri implantitis, by End User USD Million (2015-2020)
  • Table 79. Italy Peri implantitis, by Type USD Million (2015-2020)
  • Table 80. Italy Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 81. Italy Peri implantitis, by Severity USD Million (2015-2020)
  • Table 82. Italy Peri implantitis, by End User USD Million (2015-2020)
  • Table 83. United Kingdom Peri implantitis, by Type USD Million (2015-2020)
  • Table 84. United Kingdom Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 85. United Kingdom Peri implantitis, by Severity USD Million (2015-2020)
  • Table 86. United Kingdom Peri implantitis, by End User USD Million (2015-2020)
  • Table 87. Netherlands Peri implantitis, by Type USD Million (2015-2020)
  • Table 88. Netherlands Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 89. Netherlands Peri implantitis, by Severity USD Million (2015-2020)
  • Table 90. Netherlands Peri implantitis, by End User USD Million (2015-2020)
  • Table 91. Rest of Europe Peri implantitis, by Type USD Million (2015-2020)
  • Table 92. Rest of Europe Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 93. Rest of Europe Peri implantitis, by Severity USD Million (2015-2020)
  • Table 94. Rest of Europe Peri implantitis, by End User USD Million (2015-2020)
  • Table 95. MEA Peri implantitis, by Country USD Million (2015-2020)
  • Table 96. MEA Peri implantitis, by Type USD Million (2015-2020)
  • Table 97. MEA Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 98. MEA Peri implantitis, by Severity USD Million (2015-2020)
  • Table 99. MEA Peri implantitis, by End User USD Million (2015-2020)
  • Table 100. Middle East Peri implantitis, by Type USD Million (2015-2020)
  • Table 101. Middle East Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 102. Middle East Peri implantitis, by Severity USD Million (2015-2020)
  • Table 103. Middle East Peri implantitis, by End User USD Million (2015-2020)
  • Table 104. Africa Peri implantitis, by Type USD Million (2015-2020)
  • Table 105. Africa Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 106. Africa Peri implantitis, by Severity USD Million (2015-2020)
  • Table 107. Africa Peri implantitis, by End User USD Million (2015-2020)
  • Table 108. North America Peri implantitis, by Country USD Million (2015-2020)
  • Table 109. North America Peri implantitis, by Type USD Million (2015-2020)
  • Table 110. North America Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 111. North America Peri implantitis, by Severity USD Million (2015-2020)
  • Table 112. North America Peri implantitis, by End User USD Million (2015-2020)
  • Table 113. United States Peri implantitis, by Type USD Million (2015-2020)
  • Table 114. United States Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 115. United States Peri implantitis, by Severity USD Million (2015-2020)
  • Table 116. United States Peri implantitis, by End User USD Million (2015-2020)
  • Table 117. Canada Peri implantitis, by Type USD Million (2015-2020)
  • Table 118. Canada Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 119. Canada Peri implantitis, by Severity USD Million (2015-2020)
  • Table 120. Canada Peri implantitis, by End User USD Million (2015-2020)
  • Table 121. Mexico Peri implantitis, by Type USD Million (2015-2020)
  • Table 122. Mexico Peri implantitis, by Therapy Class USD Million (2015-2020)
  • Table 123. Mexico Peri implantitis, by Severity USD Million (2015-2020)
  • Table 124. Mexico Peri implantitis, by End User USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Peri implantitis: by Type(USD Million)
  • Table 136. Peri implantitis Non-surgical treatment , by Region USD Million (2021-2026)
  • Table 137. Peri implantitis Surgical treatment , by Region USD Million (2021-2026)
  • Table 138. Peri implantitis: by Therapy Class(USD Million)
  • Table 139. Peri implantitis Class-1 , by Region USD Million (2021-2026)
  • Table 140. Peri implantitis Classs-2 , by Region USD Million (2021-2026)
  • Table 141. Peri implantitis Class-3 , by Region USD Million (2021-2026)
  • Table 142. Peri implantitis Class-4 , by Region USD Million (2021-2026)
  • Table 143. Peri implantitis: by Severity(USD Million)
  • Table 144. Peri implantitis Early(PD>=4mm) , by Region USD Million (2021-2026)
  • Table 145. Peri implantitis Moderate(PD>=6mm) , by Region USD Million (2021-2026)
  • Table 146. Peri implantitis Advanced(PD>=8mm) , by Region USD Million (2021-2026)
  • Table 147. Peri implantitis: by End User(USD Million)
  • Table 148. Peri implantitis Hospitals , by Region USD Million (2021-2026)
  • Table 149. Peri implantitis Clinics , by Region USD Million (2021-2026)
  • Table 150. South America Peri implantitis, by Country USD Million (2021-2026)
  • Table 151. South America Peri implantitis, by Type USD Million (2021-2026)
  • Table 152. South America Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 153. South America Peri implantitis, by Severity USD Million (2021-2026)
  • Table 154. South America Peri implantitis, by End User USD Million (2021-2026)
  • Table 155. Brazil Peri implantitis, by Type USD Million (2021-2026)
  • Table 156. Brazil Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 157. Brazil Peri implantitis, by Severity USD Million (2021-2026)
  • Table 158. Brazil Peri implantitis, by End User USD Million (2021-2026)
  • Table 159. Argentina Peri implantitis, by Type USD Million (2021-2026)
  • Table 160. Argentina Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 161. Argentina Peri implantitis, by Severity USD Million (2021-2026)
  • Table 162. Argentina Peri implantitis, by End User USD Million (2021-2026)
  • Table 163. Rest of South America Peri implantitis, by Type USD Million (2021-2026)
  • Table 164. Rest of South America Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 165. Rest of South America Peri implantitis, by Severity USD Million (2021-2026)
  • Table 166. Rest of South America Peri implantitis, by End User USD Million (2021-2026)
  • Table 167. Asia Pacific Peri implantitis, by Country USD Million (2021-2026)
  • Table 168. Asia Pacific Peri implantitis, by Type USD Million (2021-2026)
  • Table 169. Asia Pacific Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 170. Asia Pacific Peri implantitis, by Severity USD Million (2021-2026)
  • Table 171. Asia Pacific Peri implantitis, by End User USD Million (2021-2026)
  • Table 172. China Peri implantitis, by Type USD Million (2021-2026)
  • Table 173. China Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 174. China Peri implantitis, by Severity USD Million (2021-2026)
  • Table 175. China Peri implantitis, by End User USD Million (2021-2026)
  • Table 176. Japan Peri implantitis, by Type USD Million (2021-2026)
  • Table 177. Japan Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 178. Japan Peri implantitis, by Severity USD Million (2021-2026)
  • Table 179. Japan Peri implantitis, by End User USD Million (2021-2026)
  • Table 180. India Peri implantitis, by Type USD Million (2021-2026)
  • Table 181. India Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 182. India Peri implantitis, by Severity USD Million (2021-2026)
  • Table 183. India Peri implantitis, by End User USD Million (2021-2026)
  • Table 184. South Korea Peri implantitis, by Type USD Million (2021-2026)
  • Table 185. South Korea Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 186. South Korea Peri implantitis, by Severity USD Million (2021-2026)
  • Table 187. South Korea Peri implantitis, by End User USD Million (2021-2026)
  • Table 188. Taiwan Peri implantitis, by Type USD Million (2021-2026)
  • Table 189. Taiwan Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 190. Taiwan Peri implantitis, by Severity USD Million (2021-2026)
  • Table 191. Taiwan Peri implantitis, by End User USD Million (2021-2026)
  • Table 192. Australia Peri implantitis, by Type USD Million (2021-2026)
  • Table 193. Australia Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 194. Australia Peri implantitis, by Severity USD Million (2021-2026)
  • Table 195. Australia Peri implantitis, by End User USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Peri implantitis, by Type USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Peri implantitis, by Severity USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Peri implantitis, by End User USD Million (2021-2026)
  • Table 200. Europe Peri implantitis, by Country USD Million (2021-2026)
  • Table 201. Europe Peri implantitis, by Type USD Million (2021-2026)
  • Table 202. Europe Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 203. Europe Peri implantitis, by Severity USD Million (2021-2026)
  • Table 204. Europe Peri implantitis, by End User USD Million (2021-2026)
  • Table 205. Germany Peri implantitis, by Type USD Million (2021-2026)
  • Table 206. Germany Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 207. Germany Peri implantitis, by Severity USD Million (2021-2026)
  • Table 208. Germany Peri implantitis, by End User USD Million (2021-2026)
  • Table 209. France Peri implantitis, by Type USD Million (2021-2026)
  • Table 210. France Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 211. France Peri implantitis, by Severity USD Million (2021-2026)
  • Table 212. France Peri implantitis, by End User USD Million (2021-2026)
  • Table 213. Italy Peri implantitis, by Type USD Million (2021-2026)
  • Table 214. Italy Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 215. Italy Peri implantitis, by Severity USD Million (2021-2026)
  • Table 216. Italy Peri implantitis, by End User USD Million (2021-2026)
  • Table 217. United Kingdom Peri implantitis, by Type USD Million (2021-2026)
  • Table 218. United Kingdom Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 219. United Kingdom Peri implantitis, by Severity USD Million (2021-2026)
  • Table 220. United Kingdom Peri implantitis, by End User USD Million (2021-2026)
  • Table 221. Netherlands Peri implantitis, by Type USD Million (2021-2026)
  • Table 222. Netherlands Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 223. Netherlands Peri implantitis, by Severity USD Million (2021-2026)
  • Table 224. Netherlands Peri implantitis, by End User USD Million (2021-2026)
  • Table 225. Rest of Europe Peri implantitis, by Type USD Million (2021-2026)
  • Table 226. Rest of Europe Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 227. Rest of Europe Peri implantitis, by Severity USD Million (2021-2026)
  • Table 228. Rest of Europe Peri implantitis, by End User USD Million (2021-2026)
  • Table 229. MEA Peri implantitis, by Country USD Million (2021-2026)
  • Table 230. MEA Peri implantitis, by Type USD Million (2021-2026)
  • Table 231. MEA Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 232. MEA Peri implantitis, by Severity USD Million (2021-2026)
  • Table 233. MEA Peri implantitis, by End User USD Million (2021-2026)
  • Table 234. Middle East Peri implantitis, by Type USD Million (2021-2026)
  • Table 235. Middle East Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 236. Middle East Peri implantitis, by Severity USD Million (2021-2026)
  • Table 237. Middle East Peri implantitis, by End User USD Million (2021-2026)
  • Table 238. Africa Peri implantitis, by Type USD Million (2021-2026)
  • Table 239. Africa Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 240. Africa Peri implantitis, by Severity USD Million (2021-2026)
  • Table 241. Africa Peri implantitis, by End User USD Million (2021-2026)
  • Table 242. North America Peri implantitis, by Country USD Million (2021-2026)
  • Table 243. North America Peri implantitis, by Type USD Million (2021-2026)
  • Table 244. North America Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 245. North America Peri implantitis, by Severity USD Million (2021-2026)
  • Table 246. North America Peri implantitis, by End User USD Million (2021-2026)
  • Table 247. United States Peri implantitis, by Type USD Million (2021-2026)
  • Table 248. United States Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 249. United States Peri implantitis, by Severity USD Million (2021-2026)
  • Table 250. United States Peri implantitis, by End User USD Million (2021-2026)
  • Table 251. Canada Peri implantitis, by Type USD Million (2021-2026)
  • Table 252. Canada Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 253. Canada Peri implantitis, by Severity USD Million (2021-2026)
  • Table 254. Canada Peri implantitis, by End User USD Million (2021-2026)
  • Table 255. Mexico Peri implantitis, by Type USD Million (2021-2026)
  • Table 256. Mexico Peri implantitis, by Therapy Class USD Million (2021-2026)
  • Table 257. Mexico Peri implantitis, by Severity USD Million (2021-2026)
  • Table 258. Mexico Peri implantitis, by End User USD Million (2021-2026)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Peri implantitis: by Type USD Million (2015-2020)
  • Figure 5. Global Peri implantitis: by Therapy Class USD Million (2015-2020)
  • Figure 6. Global Peri implantitis: by Severity USD Million (2015-2020)
  • Figure 7. Global Peri implantitis: by End User USD Million (2015-2020)
  • Figure 8. South America Peri implantitis Share (%), by Country
  • Figure 9. Asia Pacific Peri implantitis Share (%), by Country
  • Figure 10. Europe Peri implantitis Share (%), by Country
  • Figure 11. MEA Peri implantitis Share (%), by Country
  • Figure 12. North America Peri implantitis Share (%), by Country
  • Figure 13. Global Peri implantitis share by Players 2020 (%)
  • Figure 14. Global Peri implantitis share by Players (Top 3) 2020(%)
  • Figure 15. Global Peri implantitis share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Geistlich Pharma Inc. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Geistlich Pharma Inc. (Switzerland) Revenue: by Geography 2020
  • Figure 19. Aetna Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Aetna Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Dawood & Tanner (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Dawood & Tanner (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Neoss (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Neoss (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 28. Cadila Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 29. R.N. Laboratories Pvt. Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 30. R.N. Laboratories Pvt. Ltd. (United States) Revenue: by Geography 2020
  • Figure 31. Basic Pharma Life Science Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 32. Basic Pharma Life Science Pvt. Ltd. (India) Revenue: by Geography 2020
  • Figure 33. Prachi Pharmaceuticals Private Limited. (India) Revenue, Net Income and Gross profit
  • Figure 34. Prachi Pharmaceuticals Private Limited. (India) Revenue: by Geography 2020
  • Figure 35. Geistlich Pharma Inc. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Geistlich Pharma Inc. (Switzerland) Revenue: by Geography 2020
  • Figure 37. Global Peri implantitis: by Type USD Million (2021-2026)
  • Figure 38. Global Peri implantitis: by Therapy Class USD Million (2021-2026)
  • Figure 39. Global Peri implantitis: by Severity USD Million (2021-2026)
  • Figure 40. Global Peri implantitis: by End User USD Million (2021-2026)
  • Figure 41. South America Peri implantitis Share (%), by Country
  • Figure 42. Asia Pacific Peri implantitis Share (%), by Country
  • Figure 43. Europe Peri implantitis Share (%), by Country
  • Figure 44. MEA Peri implantitis Share (%), by Country
  • Figure 45. North America Peri implantitis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Geistlich Pharma Inc. (Switzerland)
  • Aetna Inc. (United States)
  • Dawood & Tanner (United Kingdom)
  • Neoss (United Kingdom)
  • Pfizer Inc. (United States)
  • Cadila Pharmaceuticals (India)
  • R.N. Laboratories Pvt. Ltd. (United States)
  • Basic Pharma Life Science Pvt. Ltd. (India)
  • Prachi Pharmaceuticals Private Limited. (India)
  • Geistlich Pharma Inc. (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation